Scarica l'app Stockscreener
3.00
2.39%
0.07
Dopo l'orario di chiusura:
3.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$2.93
Aprire:
$2.9
Volume 24 ore:
1.78M
Relative Volume:
1.37
Capitalizzazione di mercato:
$213.80M
Reddito:
-
Utile/perdita netta:
$-292.19M
Rapporto P/E:
-0.625
EPS:
-4.8
Flusso di cassa netto:
$-208.41M
1 W Prestazione:
-2.91%
1M Prestazione:
-4.15%
6M Prestazione:
-42.86%
1 anno Prestazione:
-77.88%
Intervallo 1D:
$2.89
$3.10
Intervallo di 1 settimana:
$2.795
$3.25
Portata 52W:
$2.66
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Confronta ZNTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.00 | 213.80M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2024-06-20 | Downgrade | UBS | Buy → Neutral |
| 2024-06-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
ZNTLZentalis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Athersys (NASDAQ:ATHX) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head to Head Review - Defense World
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - Kilgore News Herald
Zentalis Pharmaceuticals expands leadership team - Investing.com India
Zentalis Pharmaceuticals Appoint Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer - citybiz
Zentalis Pharmaceuticals Announces Key Management Appointments - GlobeNewswire
Zentalis Pharmaceuticals Strengthens Leadership Team with Strategic Biotech Executive Appointments - StockTitan
The time has not yet come to remove your chips from the table: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Fmr LLC Has $18.68 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd., expected to drive Osteosarcoma market - Barchart
Osteosarcoma Market expected to rise | AlaMab Therapeutics, - openPR
Verition Fund Management LLC Buys 951,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Grants 4.5M Stock Options to New CEO, CMO & Employees | ZNTL Stock News - StockTitan
ZNTL (Zentalis Pharmaceuticals) EBITDA : $-207.96 Mil (TTM As of Sep. 2024) - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00 - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest - MarketBeat
Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
What is HC Wainwright’s Forecast for ZNTL Q3 Earnings? - Defense World
Brokers Set Expectations for ZNTL Q3 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for ZNTL FY2024 Earnings - MarketBeat
Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00 - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright - MarketBeat
Wedbush Has Positive Estimate for ZNTL FY2024 Earnings - MarketBeat
Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals I - GuruFocus.com
ZNTL (Zentalis Pharmaceuticals) Enterprise Value : $282.73 Mil (As of Nov. 14, 2024) - GuruFocus.com
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift - TipRanks
Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen - MarketWatch
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Zentalis Pharma Reshapes Leadership, Advances Cancer Drug Azenosertib Toward Key Trials | ZNTL Stock News - StockTitan
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Inc (ZNTL): Worth A Small Bite At $3.81 - Stocks Register
Eventide Asset Management's Strategic Reduction in Zentalis Phar - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Zentalis Pharmaceuti - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Zentalis stock hits 52-week low at $2.82 amid market challenges - Investing.com Canada
Undervalued Opportunities: US Penny Stocks To Watch In October 2024 - Simply Wall St
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings - Yahoo Finance
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Stock sold by Insider Vultaggio Vincent for $5098.0 - Knox Daily
Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News - Yahoo Finance
Balance Sheet Insights: Zentalis Pharmaceuticals Inc (ZNTL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Zentalis Pharmaceuticals Inc (ZNTL)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 26.2% - MarketBeat
ZNTL Shares Experience Decline in Value - Knox Daily
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.78 Consensus Price Target from Brokerages - MarketBeat
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zentalis Pharmaceuticals Inc Azioni (ZNTL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vultaggio Vincent | Principal Accounting Officer |
Oct 04 '24 |
Sale |
3.18 |
1,603 |
5,098 |
33,855 |
| Gallagher Cam | President, Interim CFO |
May 31 '24 |
Sale |
11.98 |
9,597 |
114,972 |
633,680 |
| HAUSMAN DIANA | Chief Medical Officer |
May 09 '24 |
Sale |
12.62 |
3,356 |
42,353 |
373,876 |
| Epperly Melissa B, | Chief Financial Officer |
Feb 12 '24 |
Sale |
11.44 |
2,573 |
29,435 |
451,449 |
| Gallagher Cam | President |
Feb 12 '24 |
Sale |
11.44 |
1,173 |
13,419 |
643,277 |
| Lackner Mark | Chief Scientific Officer |
Feb 02 '24 |
Sale |
11.54 |
1,585 |
18,291 |
195,728 |
| Paul Andrea | Chief Legal Officer |
Feb 02 '24 |
Sale |
11.54 |
3,310 |
38,197 |
149,973 |
| Gallagher Cam | President |
Feb 02 '24 |
Sale |
11.54 |
11,552 |
133,310 |
644,450 |
| Epperly Melissa B, | Chief Financial Officer |
Feb 02 '24 |
Sale |
11.54 |
8,669 |
100,040 |
454,022 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):